Cancer is among the leading causes of death worldwide, with an estimated 22 million new cancer cases per year by 2025. In the Western world, there are more than 5000 new cancer survivors per day, each having to live with the risk of tumor recurrence.
Despite years of research, conventional therapies are highly invasive or non-specific and there are currently no treatment options to prevent relapse. Therefore, there is an urgent need to develop novel, efficient and more specific treatment options for cancer.
In order to address this urgent need, Immunetune was established in 2017 in Leiden, the Netherlands.
We are a dedicated and fast-moving pioneering biotech company with a highly motivated team with vast expertise in immunology, molecular biology, and a long-standing collaboration with Leiden University Medical Center.
Two patent applications related to vaccine production and immunostimulation have been filed, and the company is completing preclinical validation of its groundbreaking DNA vaccine platform.